Your browser doesn't support javascript.
loading
FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice.
Pan, Xuebo; Shao, Yihui; Wu, Fan; Wang, Yuan; Xiong, Rongrong; Zheng, Jujia; Tian, Haishan; Wang, Baile; Wang, Yanfang; Zhang, Yi; Han, Zongsheng; Qu, Aijuan; Xu, Haixia; Lu, Aihua; Yang, Tianxin; Li, Xiaokun; Xu, Aimin; Du, Jie; Lin, Zhuofeng.
Afiliação
  • Pan X; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China; The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
  • Shao Y; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Anzhen Hospital of Capital Medical University, Beijing 100029, China.
  • Wu F; Engineering Research Center of Bioreactor and Pharmaceutical Development, Ministry of Education, Jilin Agricultural University, Changchun 130118, China.
  • Wang Y; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Anzhen Hospital of Capital Medical University, Beijing 100029, China.
  • Xiong R; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
  • Zheng J; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
  • Tian H; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
  • Wang B; State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong, China.
  • Wang Y; Engineering Research Center of Bioreactor and Pharmaceutical Development, Ministry of Education, Jilin Agricultural University, Changchun 130118, China.
  • Zhang Y; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
  • Han Z; State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100730, China.
  • Qu A; Department of Pathophysiology, Capital Medical University, Beijing 100069, China.
  • Xu H; Department of Endocrinology, the 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • Lu A; Institute of Hypertension, Sun Yat-sen University, Guangzhou 510080, China.
  • Yang T; Institute of Hypertension, Sun Yat-sen University, Guangzhou 510080, China; Department of Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, UT 84132, USA.
  • Li X; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China; Engineering Research Center of Bioreactor and Pharmaceutical Development, Ministry of Education, Jilin Agricultural University, Changchun 130118, China.
  • Xu A; State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong, China.
  • Du J; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Anzhen Hospital of Capital Medical University, Beijing 100029, China.
  • Lin Z; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China; The First Affiliated Hospital of Jinan University, Guangzhou 510630, China. Electronic address: zhuofenglin@hotmail.com.
Cell Metab ; 27(6): 1323-1337.e5, 2018 Jun 05.
Article em En | MEDLINE | ID: mdl-29706566
ABSTRACT
Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. However, the role of FGF21 in hypertension remains elusive. Here we show that FGF21 deficiency significantly exacerbates angiotensin II-induced hypertension and vascular dysfunction, whereas such negative effects are reversed by replenishment of FGF21. Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in turn converts angiotensin II to angiotensin-(1-7), then inhibits hypertension and reverses vascular damage. In addition, ACE2 deficiency strikingly abrogates these beneficial effects of FGF21 in mice, including alleviation of angiotensin II-associated hypertension and vascular damage. Otherwise, pharmaceutical inhibition of angiotensin-(1-7) attenuates the protective effect of FGF21 on angiotensin II-induced vascular dysfunction, but not on hypertension. Thus, FGF21 protects against angiotensin II-induced hypertension and vascular impairment by activation of the ACE2/angiotensin-(1-7) axis via fine-tuning the multi-organ crosstalk between liver, adipose tissue, kidney, and blood vessels.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Angiotensina I / Angiotensina II / Sistema Cardiovascular / Peptidil Dipeptidase A / Fatores de Crescimento de Fibroblastos / Hipertensão Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Angiotensina I / Angiotensina II / Sistema Cardiovascular / Peptidil Dipeptidase A / Fatores de Crescimento de Fibroblastos / Hipertensão Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article